Monday, January 9, 2023

Novel T cell receptor therapy shows early anti-tumor activity

Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial.

from Latest Science News -- ScienceDaily https://ift.tt/Vq8krah
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Scientists reverse liver cell aging and cut Alzheimer’s-linked protein in half

A surprising discovery suggests that rejuvenating the liver could help protect against Alzheimer’s disease and heart disease. USC researcher...